Please Enable Cookies

www.laserfocusworld.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ: LIFE )

1.900 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.900
Bid (Size) 1.900 (15)
Ask (Size) 1.950 (20)
Prev. Close 1.900
Today's Range 1.900 - 1.900
52wk Range 1.340 - 2.150
Shares Outstanding 54,291,754
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
These 10X penny stocks have the potential to mint millionaires with enough capital but buy wisely as the risk is real. 
Via InvestorPlace
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
Ticker symbol change to take effect on Wednesday, June 5, 2024 
From aTyr Pharma, Inc.
Via GlobeNewswire

Performance

YTD
+27.09%
+27.09%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
+40.74%
+40.74%

More News

Read More
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From aTyr Pharma, Inc.
Via GlobeNewswire
Recap: aTyr Pharma Q4 Earnings
Via Benzinga
aTyr Pharma's Earnings Outlook
Via Benzinga
Analyst Expectations for aTyr Pharma's Future
Via Benzinga
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Present at Upcoming Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
aTyr Pharma to Participate in April Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
Via InvestorPlace
LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023
Via InvestorPlace
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
From aTyr Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For March 14, 2024
Via Benzinga
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
From aTyr Pharma, Inc.
Via GlobeNewswire
The 3 Best Penny Stocks to Buy in February 2024
Via InvestorPlace
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
From aTyr Pharma, Inc.
Via GlobeNewswire
Beat of Life Entertainment's 'Diya Jalao Roshni Lao' Campaign: Lighting Up Lives and Preserving Tradition!
Via IssueWire
Topics Religion
Exposures Religion
aTyr Pharma to Present at November Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
From aTyr Pharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.